What's Happening?
Shilpa Biologicals has commissioned a new antibody-drug conjugate (ADC) GMP manufacturing facility in India, designed to meet global regulatory standards including those of the U.S. FDA and EMA. The facility is fully operational, with GMP qualification
protocols underway. This development enhances Shilpa's capabilities in manufacturing highly potent compounds, positioning the company as a key player in the global ADC drug substance market. The facility aims to serve biotech and pharma partners worldwide, offering integrated ADC manufacturing solutions.
Why It's Important?
The launch of this facility is a significant milestone for Shilpa Biologicals and the Indian pharmaceutical industry, highlighting India's growing role in the global biopharmaceutical supply chain. By meeting stringent international regulatory standards, Shilpa can attract global partners and expand its market reach. This facility also underscores the increasing demand for ADCs, which are crucial in targeted cancer therapies. As the industry shifts towards more personalized medicine, the ability to produce complex biologics like ADCs will be a competitive advantage.
